Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines
Within the limitations of the data, our study finds no strong evidence for a clinically relevant difference in VITT occurring after Ad26.COV2.S or ChAdOx1 nCoV-19. Observed differences in some parameters likely result from the demographic of the populations vaccinated, and the situational and reporting differences in how, when, and where patients were identified and treated.
Authors
- Sue Pavord (ORCID: https://orcid.org/0000-0002-0840-5614)
- Nicolas Praet (ORCID: https://orcid.org/0000-0002-6680-9588)
- Hendy Kristyanto (ORCID: https://orcid.org/0000-0002-8022-6637)
- Erhan Tatar (ORCID: https://orcid.org/0000-0002-5068-4231)
- Jerald Sadoff (ORCID: https://orcid.org/0000-0002-4839-3013)
- Macaya Douoguih (ORCID: https://orcid.org/0000-0002-2707-5729)
- Yimei Xu (ORCID: https://orcid.org/0000-0003-0013-4044)
- Rian Van Rampelbergh
- Frank Struyf (ORCID: https://orcid.org/0000-0001-9988-0260)
- Karin Hardt
- Javier Ruiz‐Guiñazú (ORCID: https://orcid.org/0000-0001-6941-3100)
- Dennis J Baumgardner (ORCID: https://orcid.org/0000-0002-5699-0205)
- Vitalija van Paassen
- Luis Anaya-Velarde
- Valérie Oriol Mathieu
Institutions
- Janssen (Belgium) (BE)
- Springhouse (US)
- Oxford University Hospitals NHS Trust (GB)
- Janssen (Netherlands) (NL)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1038/s43856-025-00891-x
- Citations
- 2
- Primary Topic
- Heparin-Induced Thrombocytopenia and Thrombosis
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Janssen Research and Development